Valuation: Imunon, Inc.

Market Cap 5.72M 5.09M 4.72M 4.29M 8.1M 543M 8.23M 56.68M 22.22M 283M 21.48M 21.02M 904M P/E 2026 *
-0.42x
P/E 2027 * -0.55x
Enterprise Value 5.72M 5.09M 4.72M 4.29M 8.1M 543M 8.23M 56.68M 22.22M 283M 21.48M 21.02M 904M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day-3.77%
1 week-5.56%
Current month-20.93%
1 month-25.00%
3 months-44.26%
6 months-67.10%
Current year-73.23%
1 week 1.01
Extreme 1.0069
1.08
1 month 0.96
Extreme 0.96
1.59
Current year 0.96
Extreme 0.96
4.2
1 year 0.96
Extreme 0.96
5.2
3 years 0.96
Extreme 0.96
47.61
5 years 0.96
Extreme 0.96
197.61
10 years 0.96
Extreme 0.96
3,204.81
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Free

Chairman

7,800 0.3094%
10/9/26 Free

Chief Executive Officer

2,977 0.1181%
10/9/26 Free

Chief Technology Officer

1,249 0.0495%
Change 5-day change 1-year change 3-year change Capi.($)
-3.77%-5.56%-79.96%-92.26% 5.72M
-6.60%-8.56%+49.38%+64.90% 65B
+0.03%+5.56%+9.10%+75.22% 51.2B
-4.09%-0.11%+2.22%+55.67% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-1.07%+2.33%+19.43%+20.40% 22.5B
Average -1.87%-0.41%+32.97%+82.71% 37.24B
Weighted average by Cap. -2.20%-0.50%+44.25%+103.65%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.86M -11.92M -10.84M -20.46M -1.37B -20.79M -143M -56.17M -717M -54.3M -53.14M -2.28B -18.55M -16.49M -15.29M -13.91M -26.24M -1.76B -26.66M -184M -72.04M -919M -69.63M -68.14M -2.93B
Net Debt - -
Projected Income Statement - Annual - Imunon, Inc.
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
26-10-16 US$1.020 -3.77% 55,514
26-10-15 US$1.060 +1.92% 39,187
26-10-14 US$1.040 -2.80% 18,973
26-10-13 US$1.070 0.00% 39,589
26-10-12 US$1.070 -0.93% 42,484
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Imunon, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.020USD
Average target price
17.00USD
Spread / Average Target
+1,566.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Imunon, Inc.
  1. Stock Market
  2. Stocks
  3. IMNN Stock